ADMA BIOLOGICS INC (ADMA)
US0008991046 - Common Stock
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life Extends the...
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end...
ADMA Biologics' CFO to step down (NASDAQ:ADMA)
ADMA Biologics announces CFO transition as Brian Lenz moves to consulting role, with Grossman named as interim CFO.
ADMA Biologics GAAP EPS of -$0.08 misses by $0.11, revenue of $73.9M beats by $0.93M (NASDAQ:ADMA)
ADMA Biologics reports Q4 2023 financial results, with a miss on EPS but a beat on revenue.
ADMA Biologics Announces CFO Transition
Executive Search Initiated for CFO Replacement
ADMA Biologics Announces CFO Transition
Executive Search Initiated for CFO Replacement...
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million 4Q 2023 Adjusted EBITDA(1) of $18.6 Million; FY 2023 Adjusted EBITDA...
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Conference Call Scheduled for February 28, 2024, at 4:30 p.m. ET
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Conference Call Scheduled for February 28, 2024, at 4:30 p.m. ET...
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
January 2025 Options Now Available For ADMA Biologics
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
ADMA Biologics refinances its credit facilities with Ares Management (NASDAQ:ADMA)
ADMA Biologics secures $135M credit facility with Ares Management, using funds to repay previous debt and reduce interest rates.
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
New $135 Million Credit Facility Replaces Existing $159 Million Credit Facility, a 15% Decrease in Total Debt Further Supports Rapid Q-o-Q and Y-o-Y...
Commit To Purchase ADMA Biologics At $2.50, Earn 6% Annualized Using Options
ADMA Biologics gets label expansion for Bivigam in pediatric setting (NASDAQ:ADMA)
ADMA Biologics receives FDA approval for Bivigam, expanding treatment options for pediatric patients with primary humoral immunodeficiency.
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
Signifies the Successful Fulfillment of BIVIGAM’s Post Marketing Commitments as Part of the Original BLA Approval Expanded Label in the U.S. Now...
Why Adma Biologics Stock Crushed the Market on Friday
The network of FDA-approved collection facilities continues to grow.
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
FDA Approval Signifies the Accomplishment of ADMA’s Corporate Goal of Plasma Supply Self-Sufficiency
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
FDA Approval Signifies the Accomplishment of ADMA’s Corporate Goal of Plasma Supply Self-Sufficiency ...
Why Adma Biologics Was Trouncing the Market Today
The company beat analyst estimates for both revenue and profitability, and raised revenue guidance.
ADMA Biologics GAAP EPS of $0.01, revenue of $67.3M beats by $5.17M (NASDAQ:ADMA)
ADMA Biologics surpasses expectations in Q3 with a GAAP EPS of $0.01 and revenue of $67.3M, beating projections by $5.17M.
ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update
ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023
Conference Call Scheduled for November 8, 2023, at 4:30 p.m. ET
ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023
Conference Call Scheduled for November 8, 2023, at 4:30 p.m. ET...
Commit To Buy ADMA Biologics At $2.50, Earn 8.9% Annualized Using Options
Why Shares of ADMA Biologics Are Climbing Thursday
The company, which focuses on infectious diseases, reported its second-quarter earnings on Wednesday after the markets closed.
ADMA Biologics GAAP EPS of -$0.03 in-line, revenue of $60.13M beats by $4.63M (NASDAQ:ADMA)
ADMA Biologics press release (ADMA): Q2 GAAP EPS of -$0.03 in-line.Revenue of $60.13M (+77.4% Y/Y) beats by $4.63M.FY2024 and 2025 Total Revenue Guidance Increased to $275...